Browse articles from EyeWorld.org related to AMD. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ Last patient visit in proof-of-concept cell therapy ➤ Phase 2 data for allergic eye inflammation drop published ➤ NDA resubmission to the FDA for topical ocular reproxalap ➤ Positive topline results from Phase 2b suprachoroidal wet AMD therapy ➤ Complimentary access to video journal ➤ Partnership news ➤ ASCRS news and events
➤ FDA approves robotic OCT color fundus camera with OCTA ➤ Company to begin Phase 3 trial for Stargardt macular degeneration treatment ➤ 24-month results of oral treatment for geographic atrophy ➤ Positive Phase 2 results for investigational choroidal melanoma treatment ➤ Partnership news ➤ ASCRS news and events
➤ Study: ocular manifestations of Mpox ➤ ‘World’s first’ spiral IOL designed with artificial intelligence ➤ First-in-human implantation of wireless IOP sensor ➤ Final patient visit for Phase 2 wet AMD treatment trial ➤ Enrollment, dosing complete for Phase 1 AMD, DME therapy ➤ ASCRS news and events
➤ FDA 510(k) clearance granted to cataract surgery system ➤ Laser for POAG receives CE Mark ➤ Collaboration to develop dry eye treatment ➤ First patients enrolled in Phase 3 wet AMD trial ➤ New open-access textbook on lens power calculations ➤ ASCRS news and events
ASCRS EyeWorld Weekly: View the current issue ➤ Claes Dohlman, MD, PhD, dies at 101 years old ➤ Trial to evaluate neuropathic corneal pain drug ➤ FDA clears new OCT technology ➤ Study: supplements slow progression of late-stage dry AMD ➤ Young eye surgeon scholarship opportunity ➤ Acquisition news ➤ ASCRS news and events
➤ FDA grants De Novo classification to ocular pressure adjusting pump ➤ Inaugural ‘State of Dry Eye’ survey ➤ Study: potentially higher risk for blinding ocular condition with semaglutide use ➤ Wet AMD treatment implant reintroduced ➤ Acquisition news ➤ ASCRS news and events
➤ Prospective trial reveals impact of home OCT in wet AMD management ➤ Devices receive FDA 510(k) clearance ➤ Review date set for BLA for treatment of macular telangiectasia type 2 ➤ FDA grants IND to gene therapy for patients with geographic atrophy ➤ Acquisition news ➤ ASCRS news and events
➤ Positive topline results in trial for retinitis pigmentosa treatment ➤ Phase 2 trial for first-in-human inflammatory dry eye therapy ➤ Landmark clinical trial shows non-inferiority of Nanodropper technology ➤ Dosing complete for gene therapy aiming to help patients with Leber congenital amaurosis ➤ Enrollment begins for secondary IOL technology Phase 1 pivotal trial ➤ Strategic alignment news ➤ ASCRS news and events
➤ Enrollment complete in Phase 2 study for drug targeting endocannabinoid system for IOP lowering ➤ Dosing complete for Phase 1/2 trial evaluating a gene therapy for Stargardt disease ➤ Pre-Phase 3 Type B meeting held with FDA by company focused on retinitis pigmentosa ➤ Updates from several late-stage clinical trials ➤ New company launches to pioneer nonviral gene therapies ➤ ASCRS news and events
➤ Study: artificial intelligence matches/outperforms ophthalmologists ➤ Primary endpoint met in Phase 3 trial using an antibody to treat thyroid eye disease ➤ FDA grants Breakthrough Device Designation to novel spectacle design ➤ ASCRS news and events